A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

This Phase II study tests EGCG (epigallocatechin-3-gallate) — a natural compound found in green tea — as a treatment to help slow or prevent progression of esophageal cancer or precancerous lesions in the esophagus (food pipe). **You may be eligible if...** - You have been diagnosed with esophageal cancer or a precancerous condition of the esophagus - You are in a stable condition appropriate for the study intervention - You are at least 18 years old with adequate organ function - You are not currently receiving chemotherapy or radiation for this condition **You may NOT be eligible if...** - You have severe esophageal bleeding or obstruction - You have significant liver disease (EGCG is processed by the liver) - You are pregnant or breastfeeding - You have allergies to green tea or its components Talk to your doctor to see if this trial is right for you.